PL2718271T3 - Podstawione pochodne benzamidowe - Google Patents

Podstawione pochodne benzamidowe

Info

Publication number
PL2718271T3
PL2718271T3 PL12727633T PL12727633T PL2718271T3 PL 2718271 T3 PL2718271 T3 PL 2718271T3 PL 12727633 T PL12727633 T PL 12727633T PL 12727633 T PL12727633 T PL 12727633T PL 2718271 T3 PL2718271 T3 PL 2718271T3
Authority
PL
Poland
Prior art keywords
benzamide derivatives
substituted benzamide
substituted
derivatives
benzamide
Prior art date
Application number
PL12727633T
Other languages
English (en)
Inventor
Guido Galley
Roger Norcross
Philippe Pflieger
RENé TRUSSARDI
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46298391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2718271(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2718271T3 publication Critical patent/PL2718271T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL12727633T 2011-06-10 2012-06-06 Podstawione pochodne benzamidowe PL2718271T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11169441 2011-06-10
PCT/EP2012/060637 WO2012168265A1 (en) 2011-06-10 2012-06-06 Substituted benzamide derivatives
EP12727633.5A EP2718271B1 (en) 2011-06-10 2012-06-06 Substituted benzamide derivatives

Publications (1)

Publication Number Publication Date
PL2718271T3 true PL2718271T3 (pl) 2016-01-29

Family

ID=46298391

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12727633T PL2718271T3 (pl) 2011-06-10 2012-06-06 Podstawione pochodne benzamidowe

Country Status (32)

Country Link
US (1) US9029370B2 (pl)
EP (1) EP2718271B1 (pl)
JP (1) JP5788087B2 (pl)
KR (1) KR101574906B1 (pl)
CN (1) CN103596937B (pl)
AR (1) AR086880A1 (pl)
AU (1) AU2012266462B2 (pl)
BR (1) BR112013030698B1 (pl)
CA (1) CA2834675C (pl)
CL (1) CL2013003485A1 (pl)
CO (1) CO6811866A2 (pl)
CY (1) CY1116769T1 (pl)
DK (1) DK2718271T3 (pl)
EA (1) EA022376B1 (pl)
EC (1) ECSP13013073A (pl)
ES (1) ES2546529T3 (pl)
HR (1) HRP20151201T1 (pl)
IL (1) IL229335A (pl)
MA (1) MA35194B1 (pl)
MX (1) MX354410B (pl)
MY (1) MY162461A (pl)
PE (1) PE20140968A1 (pl)
PH (1) PH12013502263A1 (pl)
PL (1) PL2718271T3 (pl)
PT (1) PT2718271E (pl)
RS (1) RS54415B1 (pl)
SG (1) SG194840A1 (pl)
SI (1) SI2718271T1 (pl)
TW (1) TWI445701B (pl)
UA (1) UA110388C2 (pl)
WO (1) WO2012168265A1 (pl)
ZA (1) ZA201308401B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073911B2 (en) * 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
KR101631003B1 (ko) 2012-01-12 2016-06-15 에프. 호프만-라 로슈 아게 미량 아민 결합 수용체(taar)로서 헤테로환형 유도체
EA026062B1 (ru) * 2012-09-14 2017-02-28 Ф. Хоффманн-Ля Рош Аг Производные пиразолкарбоксамида в качестве модуляторов рецепторов следовых аминов (taar) для применения при лечении различных расстройств, таких как депрессия, диабет и болезнь паркинсона
HK1206714A1 (en) * 2012-09-17 2016-01-15 霍夫曼-拉罗奇有限公司 Triazole carboxamide derivatives
WO2014072257A1 (en) * 2012-11-07 2014-05-15 F. Hoffmann-La Roche Ag Pyrazine derivatives
WO2015165085A1 (en) * 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
KR101880841B1 (ko) * 2014-05-28 2018-07-20 에프. 호프만-라 로슈 아게 미량 아민 결합 수용체 1(taar1) 조절제로서 5-옥사-2-아자바이사이클로[2.2.2]옥탄-4-일 및 5-옥사-2-아자바이사이클로[2.2.1]헵탄-4-일 유도체
CN104478798B (zh) * 2014-12-18 2017-01-18 武汉华纳联合药业有限公司 N‑氨基烷基磺酰基‑3‑吡啶甲酰胺衍生物及其在制备治疗心脑血管病药物中的应用
MY195528A (en) * 2016-03-17 2023-01-30 Hoffmann La Roche 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar
CN114144412A (zh) * 2019-07-11 2022-03-04 豪夫迈·罗氏有限公司 用于制备经取代的吡唑衍生物的方法
MX2022010693A (es) * 2020-02-28 2022-09-26 Univ Texas Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades.
WO2024118488A1 (en) * 2022-11-28 2024-06-06 Sumitomo Pharma America, Inc. 2-phenylmorpholine and 2-phenyl(thio)morpholine compounds and uses thereof
WO2025165773A1 (en) * 2024-02-01 2025-08-07 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
WO2025165774A1 (en) * 2024-02-01 2025-08-07 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
BR9813381A (pt) 1997-12-04 2000-10-03 Allergan Sales Inc "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c"
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
AR050865A1 (es) * 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
WO2008026046A1 (en) 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
CL2007003874A1 (es) * 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
BRPI0806932A2 (pt) * 2007-02-02 2014-05-06 Novartis Ag Antagonista do receptor s1p1 de cromeno
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
AU2008281877A1 (en) 2007-08-02 2009-02-05 F. Hoffmann-La Roche Ag The use of benzamide derivatives for the treatment of CNS disorders
AR077969A1 (es) 2009-08-31 2011-10-05 Abbott Healthcare Products Bv Derivados de (tio)morfolina comomoduladores de s1p
CA2771822C (en) 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
US9073911B2 (en) * 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives

Also Published As

Publication number Publication date
US9029370B2 (en) 2015-05-12
MY162461A (en) 2017-06-15
SG194840A1 (en) 2013-12-30
UA110388C2 (xx) 2015-12-25
TWI445701B (zh) 2014-07-21
CA2834675C (en) 2019-09-03
IL229335A0 (en) 2014-01-30
BR112013030698B1 (pt) 2022-05-31
TW201307308A (zh) 2013-02-16
EP2718271A1 (en) 2014-04-16
KR101574906B1 (ko) 2015-12-04
MX2013014371A (es) 2014-01-31
HRP20151201T1 (hr) 2015-12-04
EA201391815A1 (ru) 2014-04-30
AU2012266462B2 (en) 2016-09-22
EA022376B1 (ru) 2015-12-30
SI2718271T1 (sl) 2015-11-30
PE20140968A1 (es) 2014-08-06
DK2718271T3 (en) 2015-08-24
IL229335A (en) 2016-11-30
AR086880A1 (es) 2014-01-29
US20120316165A1 (en) 2012-12-13
AU2012266462A1 (en) 2013-10-31
CL2013003485A1 (es) 2014-09-12
JP5788087B2 (ja) 2015-09-30
MA35194B1 (fr) 2014-06-02
ES2546529T3 (es) 2015-09-24
WO2012168265A1 (en) 2012-12-13
BR112013030698A2 (pt) 2016-12-06
NZ616820A (en) 2015-11-27
RS54415B1 (sr) 2016-04-28
HK1192562A1 (zh) 2014-08-22
PH12013502263A1 (en) 2016-06-29
CO6811866A2 (es) 2013-12-16
CY1116769T1 (el) 2017-03-15
PT2718271E (pt) 2015-10-29
ECSP13013073A (es) 2014-01-31
CN103596937B (zh) 2016-06-29
ZA201308401B (en) 2014-08-27
JP2014516067A (ja) 2014-07-07
CN103596937A (zh) 2014-02-19
KR20140028102A (ko) 2014-03-07
MX354410B (es) 2018-03-05
EP2718271B1 (en) 2015-08-12
CA2834675A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
IL286152A (en) Modified imidazopyridinyl-aminopyridine compounds
SG10201601802YA (en) Dispiropyrrolidine derivatives
ZA201401884B (en) New dihydroquinoline-2-one derivatives
GB201107176D0 (en) Pyrrolnitrin derivatives
ZA201308401B (en) Substituted benzamide derivatives
PL2772490T3 (pl) Aminoalkilo-podstawiona pochodna n-tienylobenzamidu
SG11201401937YA (en) New aryl-quinoline derivatives
IL247640A0 (en) History of heteroaryl piperidine
SG11201406871UA (en) Benzamide derivative
EP2687531A4 (en) TETRAHYDROCARBOLINE DERIVATIVE
IL231764A (en) History of 2-oxo-piperidinyl
EP2740730A4 (en) DIBENZOOXEPINE DERIVATIVE
ZA201207903B (en) Novel benzamide derivatives
IL233001A0 (en) New iso-ergoline histories
SI2766342T1 (sl) Derivati fenil-gvanidina
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
ZA201209319B (en) Cyclopropyl-indole derivatives
GB201121669D0 (en) Formula 1 - 2050
GB201121656D0 (en) Formula 1 - 2050
GB201117537D0 (en) Citizen-activated-police-response citizen activated-emergency-response
GB201119592D0 (en) Novel heteroaromatic Derivatives I
GB201108136D0 (en) Hwbh - 1